/ARCT

Arcturus Therapeutics Holdings Inc

ARCT

$15.19USD↓-6.06%-0.98 today

MARKET CAP

439.0M

P/E (TTM)

—

FWD P/E

—

DAY RANGE

$14 – $16

52W RANGE

$6

$24

AI Summary

Stalk

Sell NowHigh

ARCT is entrenched in a Stage 4 decline with sequential lower highs and lows and persistent selling pressure. Price remains below down-sloping 9/21/50 EMAs and the 50/200 DMAs, and recent tests into the EMA band have been rejected. Oversold conditions show no exhaustion, reinforcing bearish momentum. With no mean-reversion eligibility and a Speculative strategy focus on clear structural asymmetry, execution now into the EMA resistance zone aligns with optimal risk-reward on the downside.

↑Holds $191.5 M cash runway into Q4 2028, limiting dilution.
↑ARCT-032 Phase III decision expected by end-Q4 2026.
↓Q2 revenue fell to $3.0 M; net loss of $23.8 M (−$0.84/share).

Full analysis →

Buying

3

institutions

Selling

6

institutions

New Positions

0

this quarter

Filing Period

Q2 2026

latest 13-F

13-F Holdings

Institution↕	Action↕	Shares Held↕	Value↓	Change↕	Chg %↕	Weight↕
BI Blackrock, Inc. Q2 2026	BUY	2.61 M	17.57 M	+731.00	-12.9%	0.00%
AC Aqr Capital Management LLC Q2 2026	BUY	675.01 K	4.54 M	+513.74 K	+264.3%	0.00%
MM Millennium Management LLC Q2 2026	SELL	337.00 K	2.26 M	+-141.56 K	-38.7%	0.00%
PA Point72 Asset Management, L.P. Q2 2026	BUY	231.58 K	1.56 M	+167.74 K	+215.7%	0.00%
JC Jpmorgan Chase & Co Q2 2026	SELL	195.70 K	1.33 M	+-2.11 K	-2.2%	0.00%
CA Citadel Advisors LLC Q2 2026	SELL	40.95 K	275.16 K	+-111.24 K	-76.6%	0.00%
BH Brevan Howard Capital Management LP Q2 2026	SELL	28.76 K	193.28 K	+-3.98 K	-23.5%	0.00%
RT Renaissance Technologies LLC Q2 2026	SELL	21.40 K	143.81 K	+-156.90 K	-89.5%	0.00%
AC Adar1 Capital Management, LLC Q2 2026	SELL	0.00	0.00	+-15.00 K	-100.0%	0.00%